Noona has teamed up with its first two front row Scientific Advisors. Professor George Sledge is Chief of Division of Oncology at Stanford University Medical Center. Professor Ethan Basch is Director of the Cancer Outcomes Research Program, and Professor at UNC-Chapel Hill Department of Medicine.
”This is the dream come true for Noona. Working with Professor Sledge and Professor Basch will give us a tremendous competitive advantage – really taking us to the next level. Our shared mission is to build a game-changing mobile service for monitoring cancer care and follow-up. Therefore we are extending our cooperation to include both R&D and clinical research. The goal is to bring patient reported outcomes into the clinical workflow in order to decrease severe symptoms, increase satisfaction, save clinic resources and avoid emergency room admissions.” says Jani Ahonala, CEO of Noona Healthcare.
Disrupting clinical trials in Oncology?
In the near future Noona will be able to offer pharma companies and healthcare payers a unique tool to collect and analyze health outcomes of individual cancer treatments. There are currently hundreds of new cancer molecules in late stage trials. Noona’s unique user experience and strong patient engagement offer a novel opportunity to collect real world data quickly and cost-efficiently in all cancer types. So far, over 70 % of patients have started using Noona upon request. More than 90 % of these patients use Noona in ways that allow us to retrieve scientifically valuable data.
”Our vision is to build the world’s biggest data base on cancer patients’ wellbeing and symptoms by 2020. And the true beauty of it all,” Ahonala concludes, “is that every data point is produced by a patient.”
GEORGE W. SLEDGE JR., M.D.
Professor, and Chief, Division of Oncology, Stanford University Medical Center.
Dr. George W. Sledge, Jr., M.D. is Professor and Chief of Medical Oncology at Stanford University Medical Center. Dr. Sledge served as a Ballve-Lantero Professor of Oncology of Medicine and Pathology of Indiana University School of Medicine. He served as Co-Director of the breast cancer program at the Indiana University Cancer Center, where he was a Professor of Medicine and Pathology at the Indiana University Simon Cancer Center. Dr. Sledge specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. His recent research focuses on novel biologic treatments for breast cancer. He served as a Professor of Indiana University Cancer Center Breast Cancer Program. He has also served as the chair of ASCO’s Education Committee, as a member of the Department of Defense Breast Cancer Research Program’s Integration Panel, as a member of the Food and Drug Administration’s Oncology Drug Advisory Committee (ODAC), and as a member of the External Advisory Committee for The Cancer Genome Atlas (TCGA) project. Dr. Sledge was awarded the Hope Funds for Cancer Research 2013 Award of ‘Excellence for Medicine’. He holds a B.A. from the University of Wisconsin and an M.D. from Tulane University.
ETHAN BASCH, M.D., MSc
UNC Lineberger Comprehensive Cancer Center member, Director of Cancer Outcomes Research Program, and Professor in UNC-Chapel Hill Department of Medicine in the Division of Hematology and Oncology.
Dr. Basch is a medical oncologist and health services researcher. His clinical expertise is prostate cancer, and his research expertise includes patient-reported outcomes, drug regulatory policy, and comparative effectiveness research. He is a federally appointed member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), a member of the Board of Directors of the International Society for Quality of Life Research (ISOQOL), Co-Chair of the Health Outcomes Committee of the Alliance for Clinical Trials in Oncology, and a member of the Board of Scientific Advisors of the National Cancer Institute. He leads an ongoing NCI initiative to develop a patient-reported adverse event monitoring system for use in clinical research (the “PRO-CTCAE”), and is study chair for multiple trials employing patient-reported endpoints.